Nutriband Inc. (NASDAQ: NTRB) announced that it has received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. This step, dated September 2, moves the company closer to securing trademark protection for the product that incorporates its proprietary AVERSA™ abuse-deterrent technology.
The USPTO will publish the trademarks in the Trademark Official Gazette, initiating a 30-day opposition period. If no objections are filed, the USPTO is expected to issue a Notice of Allowance, which is a significant milestone for the company's branding strategy. Nutriband develops prescription transdermal pharmaceutical products, and its lead candidate is a fentanyl patch designed to deter abuse, misuse, and accidental exposure, addressing a critical public health concern associated with opioid medications.
The company highlighted the potential market opportunity, estimating peak annual U.S. sales of $80 million to $200 million for the product. This projection underscores the commercial significance of the abuse-deterrent fentanyl patch, which could offer a safer alternative to existing fentanyl products. The AVERSA™ technology is already protected by patents issued in 46 countries, providing a robust intellectual property foundation for the product's global market potential.
The trademark publication is a procedural yet crucial step in establishing a recognizable and legally protected brand for the product upon commercialization. Securing trademarks early ensures that the company can build brand equity without infringement risks. This move is part of Nutriband's broader strategy to bring its abuse-deterrent technology to market, which could have far-reaching implications for opioid safety.
The abuse of prescription opioids, including fentanyl, has led to a public health crisis. Fentanyl is up to 100 times more potent than morphine, and its misuse can be fatal. Nutriband's AVERSA™ technology aims to mitigate these risks by incorporating features that make the patch resistant to abuse, such as preventing extraction of the active ingredient for injection or inhalation. The successful development and approval of this product could provide healthcare providers with a valuable tool to manage pain while reducing the potential for diversion and accidental exposure.
Investors are closely watching Nutriband's progress, as the company's focus on abuse-deterrent formulations addresses a growing demand from regulators and healthcare providers. The U.S. Food and Drug Administration (FDA) has encouraged the development of abuse-deterrent opioids, and products with such properties may receive expedited review or market exclusivity. Nutriband's advance in trademark protection is an indicator of its commitment to bringing this product to market.
For more information about Nutriband and its pipeline, visit the company's newsroom at https://ibn.fm/NTRB.
